Clinical Trial

Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)

Name: Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a) — clinical trial record (NCT07327840)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a phase 2, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to evaluate the efficacy and safety of Kylo-11 administered subcutaneously compared to placebo in participants with ASCVD and elevated Lp(a).

Protocol Amendment History 1 change

notable Trial sites expanded: 43 -> 59 locations 2026-06-26

Trial Details

NCT Number	NCT07327840
Lead Sponsor	Kylonova (Xiamen) Biopharma co., LTD.
Conditions	Lipoprotein Disorder
Enrollment	204 participants
Start Date	2025-10-29
Primary Completion	2027-02-28 (estimated)
Study Completion	2028-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-25